




Hemorrhage Incidance with Low Molacular
Waight Heparin vs Unfractionatad Haparin in
Patients with Unatebla Angina or Non-Q-wave
Myocardial Infarction
Demers, G.J. Fromell, R.M. Califf, A.G.G. Turpie, E. Gurtinkel,
A. Langer, K.A. Fox for the ESSENCE Study. Allegheny UrriversifyHospital,
Philadelphia PA, USA
Studies of enoxaparin, a low molecular weight heparin (LMWH), and unfrac-
tionated heparin (UH) in deep vein thrombosis treatment show comparable
rates of hemorrhage in both groups. A large study in orthopedic surgery
showed no heparin induced thrombocytopenia (HIT) in the LMWH (enoxa-
parin) group compared to the UH group. The ESSENCE study was a ran-
domized, double-blind, placebo-controlled study of 3172 patienta comparing
enoxaparin 1 mglkg sc bid vs adjusted-dose UH via continuous IV infusion.
Patienta within 24 hours of onset of acute myocardial iachemia were eligible
and trial therapy was administered for a minimum of 48 hours to a maximum
of eight days. The predefine primary safety endpoints of major hemorrhage
(hemorrhage associated with a >3 gtidl Hg drop or ? 2 unit PRBCtransfu-
sion), minor hemorrhage, and the incidence of possible HIT were analyzed.
Ffesu/ts:The mean duration of therapy was 3.2 days. The overall rates of
hemorrhage for the index hospitalization were: major hemorrhage 7%, minor
hemorrhage 10%. Sixty-eight percent of major hemorrhages occurred after
discontinuation of study therapy in the setting of CABG. Overall rate of pos-
sible HIT: 0.3Y0.The incidence of primary safety endpoints in the LMWH vs
UH treatment groups will be presented.
11033-36] Evaluation of thepredictiveperfcwmance ofa
Multi-Demographic Based Heparin Doaing
Protocol in Acuta Coronary Syndromes
T,C. Trujillo, P.E. Nolan, Jr., R.A. Quan, M.K. Slack, G.A. Ewy. The
University of Arizona, Tucson,AZ, USA
Recent literature eupporta the concept that achieving a therapeutic APIT
with heparin can improve patient outcome in patients with unstable angina
(USA) and acute myooerdial infarction (AMI). Dosing heparin via a weight-
based protocol has become the standard of practice, but weight accounts
for only approximately 30% (~ = 0.30) of the variance of the heparin dose.
We hypothesized that other patient specific variables may be predictive of
heperin dosing requirement, and that integration of these variables into a
dosing protocol would further optimize anticoagulation with heparfn in USA
and AMI. A retrospective chart analysis on 140 patients with the diagnosis of
usA or AMI and treated with IV hepatin was conducted. Multiple re9rassion
analysis identified height, total body weight, age, gender and diagnosis
(AMI or USA) as being predictive of heparin requirements. (~ = 0.47). A
dosing nomogram was developed and implemented in November, 1995.
Performance of the nomogram was evaluated over a 6-month period and
compared to the original 140 patient data set. interim analysis (n = 102)
showed the nomogram significantly improved the parcentsge of patients with
a therapeutic AP~ (60-85 seconds) within 24 hours from 40% to 91% (p
< 0.001). There were no major bleeding episodes. Conclusion: The use of
a multidemogrsphic beeed heperin dosing protocol significantly improved
heparin therapy in patients with acute coronary syndromes. The comparison
of the multidemographic nomogram vs. a standard weight-based protocol
seems justified at this time.
m103337 Is There A Role For IV Heparin In Unstable Angina
Patients Prior to PTCA?
.S.R. Gangaaani, C. Dmuchowski, C.L. Grines. kVi//iarrrBeaumont Hospital,
Royal Oak, Ml, USA
The optimal timing of PTCA in unsleble angina (USA) pts is controversial.
Esrfy reporfa suggested that the risk of PTCA may be decreased in pts who
have been stabilized with aspirin and IV heparin for several daye..However
these studies were limited by the fact that medically refractory USA was
likely reason for eaffier PTCA, and more critically ill pts are known to have
a higher event rate. The purpose of this study was to evaluate whether
delaying the PTCA in order to stabilize the plaque affected the outcome.
We reviewed the hospital course of all pts admitted over one year period
with USA whoae symptoms were severe enough to raquire emergency room
evaluation and admission to rule out Ml, and required PTCA during the index
hospitalization. Of the 305 pts, 166 pte received <46 hrs (Group 1)and
139 pta received >48 hre (Group 11)of IV hepsrin before PTCA. Both the
groups were well matched. The procedural success was aimilar in both the
groups (98Y0vs 97% p = 0.72). The complication rate was similar in both
the groupa including abrupt cloaure (lYo vs 3%), emergency CABG (1.8% vs
0.7%), CK leak (4% vs 2%), Non Q Ml (3% vs 2.8Yo),Q wave Ml(0.6~0vs
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O)and death (0.6% vs 0.7%). Length of the hospital stay was significantly
prolonged in Group IL On multivariable analysis, the no. of diseased vessels
and presenting EGGwere predictive of events but not the duration of heperfn
infusion. Conclusion: In USA pts. undergoing PTCA, IV heparin infusion did
not influence the procedural outcome or post-procedural complications, but
prolongs the hospital stay. These data suggeat that early PTCA of USA pts
is safe and may be cost effective.
11033-381 COIllbinin~ilb/,kslnhibitiOnandHeparinforAcute
Coronary Syndromea: Evidence of a Gradient for
Bleading Hazard from tha PARAGON Randomized
Factorially Designed Trial
R.A. Barrington, L.K. Newby, D.J. Moiiterno, M. Bhapkar, P.W.Armstrong,
R.J. Simes, H.D. White, F.Van de Werf, A. Rames, E.J. Topol, R.M. Califf
for the PARAGON Investigators. Duke C/irrice/Research krstitute, Durham,
NC, USA
Combining potent antiplatelet with heparin therapy for acute coronaty syn-
dromes may improve clinical outcomes. The risk of increased serious bleed-
ing is unknown. PARAGON A enrolled 2282 pts with unstable angina/non-Q
Ml inamulticenter, international randomized trial of 2doees (1 or5@min) of
Iamifiban (LLand HL), anonpeptide platelet glycoprotein llb/llla inhibitor, with
or without heparin (H), versus H and aspirin. Bleeding was classified as inter-
mediate (IB) when a blood transfusion was required or the Hgb dropped >5
gldl without hemodynamic instability and as major (MB) when hemodynamic
instability occurred. Bleeding outcomes by treatment follow:
LL,H LL,noH HL,H HL,noH
(n=377) (n=378) (n= 373) (n= 396) ; = 7ae)
IB 6.8°L 4.s”/0 10.5% 8.3°h 4.8%
MB 0.5% 0.8% 2.4Y0 1.5% 0.8%
Transfusions 8.1% 4.0% 8.9”/. S.9”A 4.7%
Hem. CVA 0.3”/. 0.3% 0.0 0.0 0.0
In this ficst randomized trial of GP llb/llla inhibition with and without H,
there is a definite incremental gradient of bleeding hazard Combination
therapy with H and HL appeara especially problematic. Therapeutic strate-
gies combining both types of antithrombotic therapy need to consider this
incremental risk.
I 1033-39 I EndpointAdjudication byaClinical Events
Committea Can Impact the Statistical Outcome of
a Clinical Trial: Resulta From GUSTO-llb
K.W. Mahaffey,C.B. Granger, B.E. Tardiff, L. Woodlief, K.L. Lee,
W.D. Weaver,.E.J. Topol, R.M. Califf for the GUSTO-llb Inveatigatora. Duke
Univarsify Durham, NC, USA
A blinded centralized Clinical Events Committee (CEC) review process waa
usad to adjudicate suspected reinfarction endpoints in the GUSTO-llb trial in
which 12,142 patients with acute coronary syndromes were randomized to
heparin or desirudin. We compared the prima~ endpoint (30-day death or
reinfarction) as repotted on the Case Report Form (CRF) with that reported
by the CEC:
Desirudin Heparin P-value
CRF 8.4”/n 9.6% 0.016
CEC S.9% 9.8% 0.058
Although more patiants were identified as having reinfarofions by the CEC
process, the CEC date showed a 3.3% lower relative risk reduction of the
primary endpoint compared with the CRFdate and the statistical aignifioenoe
was leas. There were 359 reinfarctions about which the site and the CEC
dieagreed. Patients identified on the CRF but not by the CEC more offen had
chest pain and had higher median CPK values (744 vs. 629, p = 0.21).
Primary endpoint event rates determined by the CEC or the site inves-
tigator were only modestly different but the perceived effect on the overall
p-value was substantial. Whether this is due to random chance or a differ-
ence in identification and adjudication of suspected events by the systematic
review process used by the CEC is not known, but are important implications
for future clinical trials.
